New Intranasal Anxiety Therapy Under Development
The investigational treatment aims to provide faster relief for those with anxiety through a new delivery method.
Updated on Oct. 22, 2026 in Wellness
Live Poll
Do you trust that pharmaceutical companies prioritize patient needs over the potential size of a market?
Prognica Labs and Pinnacology Research & Development have formed a partnership to co-develop an investigational intranasal microemulsion therapy for anxiety. This new approach seeks to address limitations in current treatments, with initial development focused in India.
Why it matters
Current anxiety treatments often require weeks to take effect or carry risks of sedation and dependence. By exploring a novel delivery method, developers hope to create an alternative that offers faster relief without the drawbacks of existing fast-acting medications.
The global anxiety treatment market is currently valued at 12.3 billion USD, with a projected growth to 17.6 billion USD by 2035. The investigational intranasal therapy is in early-stage development, meaning its safety and clinical efficacy have not yet been established.
The players
Prognica Labs
A Dubai-based firm specializing in AI-enabled drug discovery and development.
Pinnacology Research & Development
An India-based research organization focused on pharmaceutical formulation and delivery systems.
The details
The therapy combines phytochemicals like flavan-3-ols with aromatic resin extracts in an intranasal microemulsion. This delivery route is designed to bypass traditional oral administration paths, potentially changing how the body absorbs treatment. Prognica Labs will utilize its AI-enabled discovery platform alongside Pinnacology's research to refine the formulation and regulatory strategy.
Timeline
In 2021, 359 million people lived with anxiety disorders worldwide.
The global anxiety treatment market was estimated at 12.3 billion USD in 2025.
Prognica Labs and Pinnacology announced their partnership on October 22, 2026.
The anxiety treatment market is projected to reach 17.6 billion USD by 2035.
Health Landscape
The partnership reflects a growing focus on the global anxiety treatment market, which is expanding at a compound annual growth rate of 3.6%. As demand grows, research is shifting toward novel delivery methods that aim to improve upon the limitations of current standards of care.
This investigational therapy is not currently available for patient use and has not been proven safe or effective. Any concerns regarding the side effects or onset times of your current anxiety medications are important to discuss with your doctor rather than seeking experimental alternatives.
The takeaway
While new research into anxiety treatments is ongoing, many current options for anxiety carry risks that your doctor can help you navigate. Always consult with a healthcare professional about the risks and benefits of your specific treatment plan before considering any changes.
Further reading
For more information on managing mental health, visit our Wellness section.
Live Poll
Do you trust that pharmaceutical companies prioritize patient needs over the potential size of a market?
